Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Sanofi Genzyme.

This program is not part of the official ACTRIMS Forum 2019.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2019
Physicians’ Education Resource ®, LLC.
All rights reserved.

ACTRIMS: An Interactive, Case-Based Discussion: Interpreting the Therapeutic Landscape in Multiple Sclerosis

ACTRIMS: An Interactive, Case-Based Discussion: Interpreting the Therapeutic Landscape in Multiple Sclerosis


March 2, 2019
6:30 AM - 7:45 AM

Hilton Anatole
NEW LOCATION: Monet Room on the Mezzanine Level
2201 North Stemmons Freeway
Dallas, TX 75207

Activity Overview

The treatment landscape for multiple sclerosis (MS) has changed substantially over the last several years, including the emergence of novel oral therapies and disease-modifying treatments (DMTs). With a growing number of approved therapeutic options, clinicians have a greater opportunity to tailor therapy for individual patients based on disease severity, treatment efficacy and tolerability, and considerations for lifestyle, adherence, preferences, and concerns.

Clinicians need to stay informed about the latest research on novel therapies that, if approved, could enhance the therapeutic landscape and improve patient outcomes. Failure to initiate an early and efficacious treatment plan with highly effective novel therapies, along with strategies to manage common side effects, can result in missed opportunities to preserve or improve a patient’s long-term functioning and quality of life.

An Interactive, Case-Based Discussion: Interpreting the Therapeutic Landscape in Multiple Sclerosis will bring together renowned experts for an interactive symposium to discuss specific issues relevant to practicing clinicians caring for patients diagnosed with MS. This activity will involve in-depth panel discussions of challenging clinical cases in conjunction with an audience response system to assess knowledge gaps, practice patterns (ie, “How would you treat this patient in light of the data?”), interpretation of clinical trial data, and changes in practice preference (pre-test versus post-test results) among participants.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Sanofi Genzyme.

Target Audience

This educational program is directed toward all attendees of the 2019 ACTRIMS Forum, including neurologists and MS subspecialists. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with MS will be invited to participate.

Benefits of participating in An Interactive, Case-Based Discussion: Interpreting the Therapeutic Landscape in Multiple Sclerosis:

  • Gain insights into important indicators of MS for early diagnosis
  • Expand knowledge of current and emerging therapies for MS
  • Improve competence regarding the integration of newly approved therapies into the management of MS
  • Increase awareness of treatment-related toxicities associated with current and emerging therapeutic strategies in MS

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify key indicators of MS to improve early diagnosis and initiation of treatment
  • Analyze the efficacy and safety profile of DMTs to develop individualized treatment plans for patients with MS
  • Apply data from recent clinical trials on the role of DMTs in the existing treatment landscape and the potential for improving outcomes
  • Apply knowledge of case-based challenges to develop data-driven treatment plans based on patient-specific needs

Program Chair

Robert Bermel, MD
Staff Neurologist and Director
Mellen Center for Multiple Sclerosis
Cleveland Clinic
Cleveland, OH




Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By